{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Severe+Plaque-type+Psoriasis", "query": { "condition": "Chronic Severe Plaque-type Psoriasis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Severe+Plaque-type+Psoriasis&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T09:31:30.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02173301", "title": "A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "XP23829 400 mg QD", "type": "DRUG" }, { "name": "XP 23829 800 mg QD", "type": "DRUG" }, { "name": "XP23829 400 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr. Reddy's Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2014-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2022-04-12", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02173301" }, { "nct_id": "NCT00655564", "title": "Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Alefacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2008-05", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2018-09-11", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655564" }, { "nct_id": "NCT01163253", "title": "A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2867, "start_date": "2010-09", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 101, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01163253" }, { "nct_id": "NCT01544595", "title": "Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "Secukinumab (AIN457)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1147, "start_date": "2012-06-19", "completion_date": "2017-06-26", "has_results": true, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01544595" }, { "nct_id": "NCT01406938", "title": "Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457 150mg", "type": "DRUG" }, { "name": "AIN457 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 967, "start_date": "2011-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 33, "location_summary": "Fresno, California • Pasadena, California • Sacramento, California + 28 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01406938" }, { "nct_id": "NCT01636687", "title": "Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque-type Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab 150mg", "type": "DRUG" }, { "name": "Secukinumab 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2012-10-17", "completion_date": "2016-10-27", "has_results": true, "last_update_posted_date": "2018-09-27", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01636687" }, { "nct_id": "NCT01358578", "title": "Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "secukinumab (AIN457)", "type": "DRUG" }, { "name": "etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1306, "start_date": "2011-06", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358578" }, { "nct_id": "NCT01640951", "title": "4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Chronic Plaque-Type Psoriasis" ], "interventions": [ { "name": "AIN457 150 mg", "type": "DRUG" }, { "name": "AIN457 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2012-09-16", "completion_date": "2017-05-04", "has_results": true, "last_update_posted_date": "2018-05-25", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 28, "location_summary": "Fresno, California • Pasadena, California • San Francisco, California + 24 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01640951" }, { "nct_id": "NCT02074982", "title": "Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Type Psoriasis" ], "interventions": [ { "name": "AIN457 300 mg", "type": "DRUG" }, { "name": "ustekinumab 45/90 mg", "type": "DRUG" }, { "name": "placebo secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 676, "start_date": "2014-02-26", "completion_date": "2016-06-29", "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074982" }, { "nct_id": "NCT03384745", "title": "A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "M1095 (Sonelokimab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bond Avillion 2 Development LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 313, "start_date": "2018-07-31", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-06-11T09:31:30.214Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384745" } ] }